Chronic Lymphocytic Leukemia

The FDA approves generic dasatinib tablets, enhancing access and affordability for treating chronic myeloid leukemia and acute lymphoblastic leukemia.

A recent study reveals that patient-reported side effect bother significantly predicts early treatment discontinuation in cancer therapies, highlighting the importance of patient feedback.

During a live event, Mazyar Shadman, MD, MPH, discussed options for a patient with high-risk CLL as recommended by the NCCN guidelines.

Over 200 oncologists voted on their preferred treatment in second- and third-line relapsed/refractory chronic lymphocytic leukemia.

Acalabrutinib shows high efficacy and safety for treating chronic lymphocytic leukemia in older, frail patients, improving frailty scores significantly.

Umoja Biopharma's UB-VV111 receives FDA fast track designation, advancing CAR T cell therapy for relapsed/refractory B-cell malignancies.

Recent studies highlight the potential of minimal residual disease (MRD) testing to influence treatment decisions in multiple myeloma and chronic lymphocytic leukemia.

Pirtobrutinib shows significant promise in improving progression-free survival for patients with treatment-naive CLL/SLL, challenging traditional therapies.

Despite its increased use, immunoglobulin replacement therapy does not lower the risk of serious infection in patients with chronic lymphocytic leukemia.

The FDA fast-tracks birelentinib, a dual inhibitor for relapsed CLL/SLL, promising new hope for patients facing treatment resistance.

FDA expands tocilizumab-anoh's indication for treating cytokine release syndrome, enhancing treatment options for patients undergoing CAR T-cell therapy.

The RESONATE-2 trial reveals ibrutinib's long-term efficacy and safety in treating CLL/SLL, especially for high-risk patients, over nearly a decade.

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal patient selection for CLL.

Pirtobrutinib shows promising results in treating CLL, outperforming ibrutinib in a pivotal phase 3 trial, paving the way for broader applications.

AbbVie seeks FDA approval for a groundbreaking oral treatment combining venetoclax and acalabrutinib, promising a new era in CLL care.

Zydus Lifesciences gains FDA tentative approval for generic ibrutinib, enhancing access to vital cancer treatment for patients with CLL, SLL, and WM.

Promising results emerge from a phase 1b trial of azer-cel, an innovative CAR T-cell therapy, showing high response rates in DLBCL patients.

During a live event, Andrew H. Lipsky, MD, and participants discussed balancing efficacy, safety, and patient preferences when choosing CLL treatment.

New findings reveal that fixed-duration ibrutinib plus venetoclax offers long-term efficacy and safety for patients with untreated chronic lymphocytic leukemia.

Paolo Ghia, MD, PhD, discusses the takeaways from the final analysis of the phase 2 CAPTIVATE study in CLL.

A study reveals that venetoclax consolidation after BTKi therapy is effective for chronic lymphocytic leukemia, offering promising outcomes for patients.

Despite major advances, real-world data show diminishing survival outcomes and treatment-limiting toxicities in second line or later CLL treatment.

The SEQUOIA arm D study demonstrates promising outcomes for treatment-naive patients with CLL, including high-risk patients.

Pirtobrutinib shows significant benefits in progression-free survival and tolerability for relapsed CLL patients compared to standard treatments.

Zanubrutinib shows superior progression-free survival in chronic lymphocytic leukemia compared with acalabrutinib plus venetoclax, according to recent analysis.